Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 2/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6396039 | 0.97 | MGLL (0.46) | CALM1MGLLHDAC6DRD2DRD1 | |
| SCHEMBL6395985 | 0.92 | DRD2 (0.44) | CALM1MGLLDRD2DRD1TAAR1 | |
| SCHEMBL6401455 | 0.90 | CALM1 (0.44) | CALM1MGLLHDAC6DRD2DRD1 | |
| SCHEMBL6394285 | 0.89 | SLC28A3 (0.41) | CALM1MGLLAKR1B10AKR1B1CHRM2 | |
| SCHEMBL6395752 | 0.88 | MGLL (0.45) | CALM1MGLLHDAC6DRD2DRD1 | |
| SCHEMBL6399251 | 0.86 | IGF1R (0.42) | MGLLAKR1B10AKR1B1CHRM2CHRM1 | |
| SCHEMBL6397454 | 0.82 | DRD2 (0.42) | CALM1MGLLDRD2DRD1TAAR1 | |
| SCHEMBL6397091 | 0.81 | MGLL (0.41) | CALM1MGLLHDAC6DRD2DRD1 | |
| SCHEMBL6404250 | 0.81 | SLC28A3 (0.44) | CALM1MGLLHDAC6DRD2DRD1 | |
| SCHEMBL6402235 | 0.81 | MGLL (0.39) | CALM1MGLLHDAC6DRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187195-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | PEERCE BRIAN E (US) | 2005-08-25 | — | — | US | disclosed |
| US-20030162753-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187195-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | SLC34A3, SLC34A1, SLC34A2 | CALM1 2071/4885MGLL 3457/4885HDAC6 4653/4885 |
| US-20030162753-A1 | Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans | SLC34A3, SLC34A1, SLC34A2 | CALM1 2071/4885MGLL 3457/4885HDAC6 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.